TRC101 提高 CKD 患者血清碳酸氢盐的随机对照试验
TRC101 各剂量组在首次给药 72 小时内血清碳酸氢盐平均升高 ≥1.3 mEq/L(P<0.001),治疗结束时较安慰剂平均升高 3.2–3.9 mEq/L(P<0.001)。不良事件均为轻中度,以胃肠道事件最常见,所有患者均完成研究。
要点
- TRC101 可安全、显著升高 CKD 合并代谢性酸中毒患者的血清碳酸氢盐。
- 治疗结束时血清碳酸氢盐较安慰剂平均升高 3.2–3.9 mEq/L(P<0.001)。
- 停药后 2 周内血清碳酸氢盐几乎降至基线水平。
核心结论
- TRC101 可安全、显著提高 CKD 合并代谢性酸中毒患者的血清碳酸氢盐水平。
研究设计与样本
- 患者基线平均 eGFR 35 ml/min per 1.73 m2,平均血清碳酸氢盐 17.7 mEq/L。
- 患者接受控制饮食,治疗 14 天,方案为安慰剂或 TRC101 四种剂量之一(1.5、3 或 4.5 g 每日两次,或 6 g 每日一次)。
- 治疗后出院随访 7–14 天。
主要发现
- 所有 TRC101 治疗组在首次给药 72 小时内血清碳酸氢盐平均组内升高 ≥1.3 mEq/L(P<0.001)。
- 治疗结束时 TRC101 组血清碳酸氢盐较安慰剂平均升高 3.2–3.9 mEq/L(P<0.001),安慰剂组无变化。
- TRC101 联合治疗组治疗结束时 35% 患者血清碳酸氢盐恢复正常(22–29 mEq/L),39% 患者升高 ≥4 mEq/L。
- 停用 TRC101 后 2 周内血清碳酸氢盐几乎降至基线水平。
- 所有不良事件均为轻中度,胃肠道事件最常见,所有患者均完成研究。
关键数值与推荐
- 血清碳酸氢盐正常范围定义为 22–29 mEq/L。
- TRC101 各剂量组首次给药 72 小时内血清碳酸氢盐平均升高 ≥1.3 mEq/L(P<0.001)。
- 治疗结束时 TRC101 组血清碳酸氢盐较安慰剂平均升高 3.2–3.9 mEq/L(P<0.001)。
临床怎么用
- TRC101 可作为 CKD 合并代谢性酸中毒患者升高血清碳酸氢盐的治疗选择。
- 治疗期间需关注胃肠道不良事件,均为轻中度。
- 停药后血清碳酸氢盐可能回落,需监测。
局限性
- 研究为住院控制饮食条件下进行,治疗仅 14 天,随访 7–14 天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Metabolic acidosis is common in patients with CKD and has significant adverse effects on kidney, muscle, and bone. We tested the efficacy and safety of TRC101, a novel, sodium-free, nonabsorbed hydrochloric acid binder, to increase serum bicarbonate in patients with CKD and metabolic acidosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One hundred thirty-five patients were enrolled in this randomized, double-blind, placebo-controlled, multicenter, in-unit study (designated the TRCA-101 Study). Patients had a mean baseline eGFR of 35 ml/min per 1.73 m2, a mean baseline serum bicarbonate of 17.7 mEq/L, and comorbidities, including hypertension (93%), diabetes (70%), and heart failure (21%). Patients ate a controlled diet and were treated for 14 days with placebo or one of four TRC101 dosing regimens (1.5, 3, or 4.5 g twice daily or 6 g once daily). After treatment, patients were discharged and followed for 7-14 days. RESULTS: All TRC101 treatment groups had a mean within-group increase in serum bicarbonate of ≥1.3 mEq/L (P<0.001) within 72 hours of the first dose and a mean increase in serum bicarbonate of 3.2-3.9 mEq/L (P<0.001) at the end of treatment compared with placebo, in which serum bicarbonate did not change. In the combined TRC101 treatment group, serum bicarbonate was normalized (22-29 mEq/L) at the end of treatment in 35% of patients and increased by ≥4 mEq/L in 39% of patients. After discontinuation of TRC101, serum bicarbonate decreased nearly to baseline levels within 2 weeks. All adverse events were mild or moderate, with gastrointestinal events most common. All patients completed the study. CONCLUSIONS: TRC101 safely and significantly increased the level of serum bicarbonate in patients with metabolic acidosis and CKD.
引用
- Bushinsky DA, Hostetter T, Klaerner G, et al. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD. Clin J Am Soc Nephrol. 2017. PMID: 29102959. doi:10.2215/CJN.07300717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。